Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States
European Urology Focus, ISSN: 2405-4569, Vol: 8, Issue: 4, Page: 910-912
2022
- 5Citations
- 7Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef3
- Captures7
- Readers7
- Mentions1
- News Mentions1
- News1
Most Recent News
Findings on Prostate Cancer Detailed by Investigators at Yale University (Variation and Disparity In the Use of Prostate Cancer Risk Stratification Tools In the United States)
2023 AUG 01 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- New research on Oncology - Prostate Cancer is the
Review Description
In this review we summarize evidence from US studies examining variation in the use of prostate magnetic resonance imaging (MRI) and tissue-based gene expression tests (genomic tests), focusing on sources of regional and racial variation. Large observational studies indicate that prostate MRI and genomic testing vary significantly at the regional level as measured across multiple geographic boundaries. Similarly, there is lower use of prostate MRI among Black versus White-identified patients Black in comparison to those who are White, as well as evidence of less use among Hispanic and Asian versus White patients. These findings indicate opportunities to address modifiable sources of practice variation in localized prostate cancer. In this review, we found that use of prostate magnetic resonance imaging (MRI) scans and genetic testing differed by region, and race, with less prostate MRI use among Black versus White patients. These findings can help raise awareness about gaps in access to new prostate cancer tools.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2405456922001316; http://dx.doi.org/10.1016/j.euf.2022.06.003; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85133354474&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35778364; https://linkinghub.elsevier.com/retrieve/pii/S2405456922001316; https://dx.doi.org/10.1016/j.euf.2022.06.003
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know